Enhertu gains a potential first-line foothold in HER2-mutant NSCLC, but oral TKIs remain credible competitors

Recent reported topline results from the phase 3 DESTINY-Lung04 trial found Enhertu improved progression-free survival versus platinum-pemetrexed chemotherapy plus pembrolizumab when used as first-line treatment for unresectable or metastatic non-squamous NSCLC with HER2 exon 19 or 20 mutations.

The result strengthens the case for Enhertu as a potential first-line targeted option, but detailed efficacy, overall-survival, safety, and subgroup data—and regulatory review—are still needed before its competitive position is clear.

Enhertu’s current NSCLC approvals are primarily in previously treated HER2-mutant disease, so first-line use remains investigational pending regulatory action.

Oral HER2 TKIs such as zongertinib could compete through convenience, outpatient administration, and potentially favorable tolerability. Early data have shown durable responses in previously treated HER2-mutant NSCLC, but direct first-line comparisons with Enhertu are not yet established.

Enhertu may retain advantages from validated activity, broad mutation coverage, and antibody-drug-conjugate bystander killing, while TKIs may be favored for oral convenience and easier long-term administration. The likely outcome is differentiation by mutation subtype, CNS activity, toxicity, sequencing, and price rather than an immediate single-winner market.